LGC opens CAD $100 million organic chemistry Center of Excellence in Canada
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The facility has been designed with a dual focus on efficiency and sustainability
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Subscribe To Our Newsletter & Stay Updated